Akiferidin suppresses cervical cancer growth and angiogenesis via the VEGF/DLL4-Notch pathway
Cervical cancer remains a major gynecological malignancy with a substantial global burden, particularly in low- and middle-income regions. Tumor angiogenesis driven by the VEGF/DLL4–Notch axis promotes cervical cancer progression, and the anti-VEGF antibody bevacizumab shows limited clinical benefit...
Guardat en:
| Autors principals: | , , , , , |
|---|---|
| Format: | Artigo |
| Idioma: | Inglês |
| Publicat: |
Frontiers Media S.A.
2026-04-01
|
| Col·lecció: | Frontiers in Pharmacology |
| Matèries: | |
| Accés en línia: | https://www.frontiersin.org/articles/10.3389/fphar.2026.1803135/full |
| Etiquetes: |
Sense etiquetes, Sigues el primer a etiquetar aquest registre!
|